Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in Moderately Active Ulcerative Colitis – 52-Week Randomized Double-Blind Placebo-Controlled Trial
2020-003507-34Phase 2Completed
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Etrasimod with Placebo (2 arms). Primary endpoint: Clinical remission at Week 52 (Mayo score). Started Dec 2020; status: completed.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2020-003507-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003507-34.